Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 14/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5838562 | 0.88 | HTR2A (0.53) | HTR2ASLC6A4KCNH2EPAS1ERN1 | |
| SCHEMBL4939724 | 0.82 | HTR2A (0.53) | HTR2ASLC6A4KCNH2EPAS1SLC6A2 | |
| SCHEMBL5321373 | 0.80 | LMNA (0.61) | HTR2ASLC6A4KCNH2HSP90AA1SLC6A2 | |
| SCHEMBL5837555 | 0.78 | HTR2A (0.56) | HTR2ASLC6A4KCNH2EPAS1ALDH1A1 | |
| SCHEMBL5837334 | 0.78 | HTR2A (0.57) | HTR2ASLC6A4KCNH2KMO | |
| SCHEMBL6151744 | 0.78 | KMT2A (0.46) | HTR2ASLC6A4KCNH2EPAS1ERN1 | |
| SCHEMBL274863 | 0.78 | PTGDR2 (0.48) | SLC6A4PTGDR2EPAS1ERN1ALDH1A1 | |
| SCHEMBL275629 | 0.78 | LMNA (0.61) | PTGDR2ERN1ALDH1A1 | |
| SCHEMBL2075254 | 0.78 | LMNA (0.62) | SLC6A4PTGDR2ERN1ALDH1A1 | |
| SCHEMBL31287740 | 0.77 | TUBB1 (0.49) | HTR2ASLC6A4KCNH2ERN1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256122-A1 | BUTYL AND BUTYNYL BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-07 | — | — | US | disclosed |
| US-7767666-B2 | Butyl and butynyl benzyl amine compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-03 | — | — | US | disclosed |
| US-20090137562-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-28 | — | — | US | disclosed |
| EP-2049473-A2 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-22 | — | — | EP | disclosed |
| EP-2049466-A1 | BUTYL AND BUTYNYL BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-22 | — | — | EP | disclosed |
| EP-2046747-A1 | SUBSTITUTED AMINOMETHYL BENZAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-15 | — | — | EP | disclosed |
| US-7479493-B2 | Substituted benzyl amine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-20 | — | — | US | disclosed |
| US-20080045508-A1 | SUBSTITUTED AMINOMETHYL BENZAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045509-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| WO-2008002817-A1 | BUTYL AND BUTYNYL BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | WO | disclosed |
| US-6677378-B2 | AS SEROTONIN, NOREPINEPHRINE AND DOPAMINE REUPTAKE INHIBITORS, FOR THERAPY OF CENTRAL NERVOUS SYSTEM AND OTHER DISORDERS | PFIZER INC. | 2004-01-13 | — | — | US | disclosed |
| US-6596741-B2 | Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders. | PFIZER INC | 2003-07-22 | — | — | US | disclosed |
| US-20030055038-A1 | Novel biaryl ether derivatives useful as monoamine reuptake inhibitors | PFIZER INC. | 2003-03-20 | — | — | US | disclosed |
| CN-1378527-A | Biaryl ether derivatives useful as monoamine reuptake inhibitors | PFIZER PROD INC (US) | 2002-11-06 | — | — | CN | disclosed |
| US-20020143003-A1 | Monoamine reuptake inhibitors for treatment of CNS disorders | PFIZER INC. | 2002-10-03 | — | — | US | disclosed |
| EP-1220831-A1 | BIARYL ETHER DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | Pfizer Products Inc. (US) | 2002-07-10 | — | — | EP | disclosed |
| US-6410736-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-06-25 | — | — | US | disclosed |
| EP-1154984-A1 | INHIBITORS FOR UPTAKE OF SEROTONINE, DOPAMINE OR NOREPINEPHRINE | Pfizer Products Inc. (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2001027068-A1 | BIARYL ETHER DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2001-04-19 | — | — | WO | disclosed |
| WO-2000050380-A1 | MONOAMINE REUPTAKE INHIBITORS FOR TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256122-A1 | BUTYL AND BUTYNYL BENZYL AMINE COMPOUNDS | HRH3, HNMT, HRH4 | HTR2A 16/4885SLC6A4 10/4885KCNH2 1925/4885 |
| US-20080045509-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | HRH3, HNMT, HRH4 | HTR2A 15/4885SLC6A4 8/4885KCNH2 1234/4885 |
| US-20090137562-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | HRH3, HNMT, HRH4 | HTR2A 15/4885SLC6A4 8/4885KCNH2 1234/4885 |
| US-20030055038-A1 | Novel biaryl ether derivatives useful as monoamine reuptake inhibitors | SLC6A2, SLC6A3, SLC18A2 | HTR2A 24/4885SLC6A4 6/4885KCNH2 1835/4885 |
| US-20020143003-A1 | Monoamine reuptake inhibitors for treatment of CNS disorders | SLC6A2, SLC6A4, SLC6A3 | HTR2A 24/4885SLC6A4 2/4885KCNH2 1224/4885 |
| US-20080045508-A1 | SUBSTITUTED AMINOMETHYL BENZAMIDE COMPOUNDS | HNMT, HRH3, HRH4 | HTR2A 12/4885SLC6A4 6/4885KCNH2 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.